AJAgustín Jara

Agustín Jara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Agustín Jara has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent Increased Seizure Susceptibility Following Lithium-Pilocarpine-Induced Status Epilepticus

    by Claudia Taborda Gómez, Florencia Fernández, Agustín Jara, Natalia Borda, Franco Moscovicz, Yessenia Yauri-Huaman, Rodrigo Caceres-Robles, Luis F. Pacheco-Otalora, Alberto Lazarowski, Jerónimo Auzmendi

    Introduction. In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsy. In addition to its anticonvulsant effect, CBD also has well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury, and one of its main characteristics is an increased susceptibility to seizures due to a reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. Methodology. We developed an experimental protocol to discretely measure the seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/every 10 min). Results. Using the DMST, we observed a significant decrease in the seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20 mg/kg) for 14 days following SE. Conclusions. Treatment with CBD did not improve the seizure threshold; moreover, it worsened the hypersensitivity state and delayed recovery following SE. Our results suggest that orally administered CBD, at a human-equivalent therapeutic and safe dose, does not improve susceptibility to seizure development after SE.


  • Open Access

    Subchronic Cannabidiol (CBD) Treatment During the Silent Period Fails to Prevent the Increased Seizure Susceptibility Following Lithium Pilocarpine-Induced Status Epilepticus

    by Claudia Taborda, Florencia Fernandez, Agustín Jara, Natalia Borda, Franco Moscovicz, Yessenia Yauri-Huaman, Rodrigo Caceres-Robles, Luis F. Pacheco-Otalora, Alberto Lazarowski, Jerónimo Auzmendi

    In recent years, cannabidiol (CBD) has been used as an adjunct therapy to anti-seizure medications for the control of seizures in patients with drug-resistant epilepsies. In addition to its anticonvulsant effect, CBD also well-defined anti-inflammatory properties. Since neuroinflammation can trigger various pro-epileptogenic mechanisms For this reason, CBD could play an inhibitory role in this process. Epileptogenesis is the process by which epilepsy becomes a chronic disease following a brain injury and one of its main characteristics is an increased susceptibility to seizures due to reduced seizure threshold. However, the role of CBD in modulating this susceptibility remains poorly understood. We developed an experimental protocol to discretely measure seizure threshold (DMST) 7 or 14 days after lithium-pilocarpine-induced status epilepticus (SE) through the administration of small intraperitoneal (i.p.) doses of pentylenetetrazol (15 mg/kg/ every 10 minutes). Using the DMST, we observed a significant decrease in seizure threshold after SE associated with a hypersensitivity state characterized by irritability and marked weight loss. A separate cohort of rats was treated with CBD (20mg/kg) for 14 days following SE. Treatment with CBD did not improve seizure threshold, moreover, it worsened the hypersensitivity state, and delayed the recovery following SE. Our results suggest that orally administered CBD, at a human therapeutically recommended and safe dose, does not improve susceptibility to seizure development after SE.